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Introduction: The relationship between hyperoxemia and outcome in patients with traumatic brain injury (TBI) is
controversial. We sought to investigate the independent relationship between hyperoxemia and long-term
mortality in patients with moderate-to-severe traumatic brain injury.
Methods: The Finnish Intensive Care Consortium database was screened for mechanically ventilated patients with a
moderate-to-severe TBI. Patients were categorized, according to the highest measured alveolar-arterial O2 gradient
or the lowest measured PaO2 value during the first 24 hours of ICU admission, to hypoxemia (<10.0 kPa),
normoxemia (10.0 to 13.3 kPa) and hyperoxemia (>13.3 kPa). We adjusted for markers of illness severity to evaluate
the independent relationship between hyperoxemia and 6-month mortality.
Results: A total of 1,116 patients were included in the study, of which 16% (n = 174) were hypoxemic, 51%
(n = 567) normoxemic and 33% (n = 375) hyperoxemic. The total 6-month mortality was 39% (n = 435). A significant
association between hyperoxemia and a decreased risk of mortality was found in univariate analysis (P = 0.012).
However, after adjusting for markers of illness severity in a multivariate logistic regression model hyperoxemia
showed no independent relationship with 6-month mortality (hyperoxemia vs. normoxemia OR 0.88, 95% CI 0. 63
to 1.22, P = 0.43; hyperoxemia vs. hypoxemia OR 0.97, 95% CI 0.63 to 1.50, P = 0.90).
Conclusion: Hyperoxemia in the first 24 hours of ICU admission after a moderate-to-severe TBI is not predictive of
6-month mortality.
Keywords: Arterial oxygen tension, Neurocritical care, Oxygenation, Traumatic brain injury, Hyperoxemia, Intensive
care, Mortality, Mechanical ventilationIntroduction
Traumatic brain injury (TBI) is the leading cause of
mortality and morbidity among the young population
[1,2]. Hypoxemia has been shown to be detrimental after
TBI [3,4]. Accordingly, guidelines from the European
Brain Injury Consortium (EBIC) recommend an arterial
oxygen tension (PaO2) target of 13.3 kPa (100 mmHg) [5].
The Brain Trauma Foundation (BTF) guidelines recom-
mend that PaO2 values lower than 8.0 kPa (65 mmHg)
should be avoided, but due to lack of strong evidence an
upper limit of PaO2 has not been established.
Brain hypoxia (low brain tissue oxygen tension, PbtO2)
is an independent predictor of poor outcome, regardless
of intracranial pressure (ICP), cerebral perfusion pressure* Correspondence: rahul.br.raj@icloud.com
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reproduction in any medium, provided the or(CPP) and injury severity [6]. Lately, there has been grow-
ing evidence that patient outcome is improved after apply-
ing a PbtO2-targeted therapy [7,8]. In PbtO2-targeted
therapy, high inspired oxygen fraction in percent (FiO2) is
frequently used to maintain adequate PbtO2 [9,10]. As a
consequence of the high FiO2, PaO2 increases to supra-
physiological levels, that is, hyperoxemia [11]. However,
the relationship between hyperoxemia and outcome in
patients with TBI is controversial [12,13]. Some clinical
studies have reported a significant relationship between
hyperoxemia and an increased risk of death, whereas some
studies have shown no such relationship or even increased
survival for TBI patients with mild hyperoxemia [14-16].
Accordingly, we performed a retrospective observational
multicenter study using a large national database to deter-
mine the independent relationship between hyperoxemiaThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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and long-term mortality.
Materials and methods
Finnish Intensive Care Consortium database
The Finnish Intensive Care Consortium (FICC) database
is a high quality multicenter database consisting of data
from ICUs in 22 different hospitals [17]. The FICC was
established in 1994 as a cooperative benchmarking pro-
ject, the goal of which was to improve the quality of in-
tensive care in Finland. Physiological data are stored by
clinical information systems that automatically collect
data from patient monitors, ventilators and laboratory
systems. Data on comorbidities, type of admission, diag-
nosis, and outcome are entered manually by ICU staff
into the electronic database. Patients admitted after TBI
are coded as such. Data are then transferred to the cen-
tral database, which is processed by Tieto Healthcare &
Welfare Ltd. (Kuopio, Finland). Before integration to the
central database, automatic filters and specially trained
personnel validate the data.
Data collection, extraction and oxygen values
The ethical committee of the Northern Savonia hospital
district approved the study in May 2011 and following
that the FICC management committee granted us access
to the database. Data were extracted for all patients en-
tered into the FICC database between 2003 and 2012,
who had had moderate-to-severe TBI (Glasgow coma
scale (GCS) score 3 to 12) and had been admitted to a
neurosurgical hospital (five out of twenty-two hospitals).
Treatment standards in all included hospitals are
according to the BTF cerebral perfusion pressure (CPP)/
ICP-directed guidelines [6]. Patients who had been re-
admitted, were non-mechanically ventilated, or for
whom arterial blood gas analysis (ABG) or long-term
outcome data were missing were excluded. Only patients
between the ages of 14 to 99 years were included to be
able to properly compare the study population with the
nested cohort.
The FICC database contains only one PaO2 value. The
value is chosen according to acute physiology and
chronic health evaluation (APACHE) II methodology:
that is, the PaO2 value associated with the ABG (taken
during the first 24 h of ICU admission) with the highest
alveolar-arterial (A-a) gradient for patients receiving
FiO2 ≥0.5 or the ABG associated with the lowest PaO2
value for patients receiving FiO2 <0.5 (PaO2). The fol-
lowing variables were extracted from the FICC database:
diagnosis, type of admission, year of admission, APACHE
II scores [18], therapeutic intervention scoring system 76
(TISS-76) [19], treatment restrictions, comorbidities, diag-
nosis, physiological parameters, laboratory parameters in
the ICU, and in-hospital and 6-month mortality.Statistical analysis
For all statistical analyses we used SPSS Statistics for
Windows, Version 20.0, released 2011 (IBM Corp,
Armonk, NY, USA). The χ2 test (two-tailed) was used
for categorical univariate analysis. Continuous variables
were analyzed for skewness and the appropriate statis-
tical test used accordingly. All continuous variables
were highly skewed, hence, the non-parametric Mann–
Whitney U-test was used. Data are presented as median
values with IQR unless otherwise mentioned. The
Spearman correlation coefficient was used to assess
correlation between variables. The variance inflation
factor (VIF) was used to control for co-linearity be-
tween variables in multivariate analysis.
Patients were divided according to the collected PaO2
(highest alveolar-arterial O2 gradient or lowest PaO2 value).
Arterial oxygen tension levels were defined a priori to ana-
lysis: hypoxemia was defined as <10.0 kPa, normoxemia as
10.0 to 13.3 kPa and hyperoxemia as >13.3 kPa [20]. The
primary outcome was 6-month mortality and the second-
ary outcome was in-hospital mortality.
As a marker of illness severity the APACHE II score was
used. However, since PaO2 is included in the APACHE II
model (and we sought to investigate the independent rela-
tionship between hyperoxemia and mortality) an adjusted
APACHE II index of illness severity independent of PaO2
was calculated (AP2no-ox). Furthermore, age and the
GCS have been shown to be very strong independent pre-
dictors of outcome in TBI, so we tested whether the per-
formance of AP2no-ox increased when recalibrating the
index using age and the GCS as separate variables [21].
The final AP2no-ox with the best performance contained
only the GCS as a separate variable. The performance of
the APACHE II score and the calculated APACHE II
index (AP2no-ox) to predict outcome was assessed by cal-
culating the area under the curve (AUC) and the Hosmer-
Lemeshow goodness-of-fit test (RL
2).
A set of predefined potential confounding factors
was included in a multivariate analysis using logistic
regression to investigate the independent effect of
hyperoxemia on outcome. The final multivariate model
included: AP2no-ox, PaO2 groups, year of admission
(before or after 2007), emergency operation, ICP moni-
toring, controlled hypothermia, and platelet count. Fur-
thermore, the predicted probability of mortality was
calculated using multivariable analysis. A locally weighted
scatterplot smoothing (lowess) curve was used to show
the underlying relationship between PaO2 and 6-month
mortality. The RL
2 test was used to assess how predicted
and observed mortality matched.
Nested cohort analysis
Because the FICC database only contained one PaO2
value, and data regarding TBI severity were limited, we
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better understand the descriptive value of the PaO2 mea-
sured according to the APACHE II methodology. Fur-
thermore, we wanted to control for co-linearity between
TBI severity and PaO2. The nested cohort consisted of
patients with a moderate-to-severe TBI treated in the
ICU of a designated tertiary neurosurgical trauma center
(Töölö Hospital, Helsinki University Central Hospital,
Finland) between 1 January 2009 and 31 December
2010. Only patients mechanically ventilated during the
first 24 h of ICU admission were included. TBI severity
was measured using the IMPACT-TBI prognostic model.
The International Mission for Prognosis and Clinical
Trials (IMPACT)-TBI model predicts risk of 6-month
mortality based on patient admission characteristics
[21]. All ABG data during the mechanical ventilation
period were collected and used to calculate a time-
weighted average of PaO2 (TWA-O2). Furthermore, as
in the main study population, the PaO2 value associated
with the highest A-a gradient or lowest oxygen value
was collected (nPaO2). To evaluate the descriptive value
of PaO2 we tested for correlation between TWA-O2 and
nPaO2. To control for the relationship between TBI se-
verity and PaO2 correlation between TWA-O2, we tested
the nPaO2 and the IMPACT score. Correlation between
variables was tested using the Spearman correlation
coefficient.
Results
A total of 1,116 patients met the inclusion criteria
(Figure 1). Of these patients 16% (n = 174) were hyp-
oxemic, 51% (n = 567) normoxemic and 33% (n = 375)
hyperoxemic. Baseline characteristics and physiological
parameters are presented in Table 1. The median age was
53 years (IQR 35 to 64). There were some significant dif-
ferences between the PaO2 groups in baseline characteris-
tics. Hyperoxemic patients were significantly younger thanFigure 1 Study population. TBI, traumatic brain injury; FICC, Finnish Intensiv
gas analysis.normoxemic and hypoxemic patients (P <0.020). Patients
in the hypoxemic group had received a significantly
higher median FiO2 than patients in the normoxemic
and hyperoxemic groups (median FiO2 44%, 40%, 39%,
P <0.001) but had a lower PaO2/FiO2 ratio than
normoxemic and hyperoxemic patients (median PaO2/
FiO2 19, 31, and 48, respectively; P <0.001). Further-
more, it was noted that patients in the hypoxemic group
had significantly lower mean arterial pressure (MAP) than
normoxemic and hyperoxemic patients (median MAP 69,
105, and 106, respectively; P = 0.002).
Some slight variations in GCS between the groups were
noted (P = 0.047). Also, controlled hypothermia and ICP
monitoring were more frequently done in the hyperoxemia
group (P = 0.011 and 0.004, respectively). However, there
were no significant differences in overall treatment
according to the TISS-76 (P = 0.803), but hyperoxemic pa-
tients had a higher average daily TISS-76 score than
normoxemic and hypoxemic patients (P = 0.012).
The median APACHE II score for the whole cohort
was 24 (IQR 19 to 28). The score was significantly
higher in the hypoxemic group compared to the
hyperoxemic and normoxemic group (P <0.001). Median
AP2no-ox was lowest in the hyperoxemia group (28.5,
IQR 13.5 to 58.4) followed by the normoxemia group
(35.5, IQR 15.1 to 58.4) and highest in the hypoxemia
group (49.1, IQR 19.7 to 71.1) (P <0.001). The APACHE
II score showed excellent performance for predicting 6-
month mortality in our patient cohort, with an AUC of
0.80 and an RL
2 of 0.10. The APACHE II index (AP2no-ox)
also showed excellent performance for predicting 6-
month mortality, with an AUC of 0.82 and an RL
2 of 0.32.
Patients excluded due to missing data on long-term out-
come did not significantly differ in PaO2 (13.1 kPa, IQR
10.8 to 16.8) (P = 0.394), but they had a slightly lower
APACHE II score (22, IQR 19 to 26) than the included pa-
tients (P = 0.001).e Care Consortium; GCS, Glasgow coma scale; ABG, arterial blood










Age, years 53 (35, 64) 53 (34, 63) 55 (41, 66) 52 (32, 64) 0.020
Year of admission
2002 to 2007 461 (41) 83 (48) 179 (48) 199 (35) <0.001
2008 to 2012 655 (59) 19 (52) 196 (52) 368 (65)
Emergency operation 576 (52) 87 (50) 187 (50) 302 (53) 0.515
Operative admission 632 (57) 82 (47) 218 (58) 332 (59) 0.022
Controlled hypothermia 84 (8) 5 (3) 25 (7) 54 (10) 0.011
ICP monitoring 507 (46) 72 (41) 150 (40) 285 (50) 0.004
Treatment restriction 206 (19) 33 (19) 68 (18) 105 (19) 0.972
Platelets (109) 168 (118, 225) 156 (99, 231) 153 (111, 220) 174 (123, 225) 0.250
Markers of injury severity
APACHE II score 24 (19, 28) 27 (22, 32) 24 (19, 28) 23 (19, 27) <0.001
Glasgow Coma Scale
3 to 5 657 (59) 118 (68) 221 (59) 318 (56) 0.047
6 to 8 267 (24) 38 (22) 86 (23) 143 (25)
9 to 12 192 (17) 18 (10) 68 (18) 106 (19)
TISS-76 total score 133 (69, 287) 116 (69, 284) 131 (70, 278) 138 (68, 314) 0.803
TISS-76 average score 33 (29, 38) 35 (29, 39) 32 (28, 37) 33 (29, 38) 0.012
ICU length of stay, days 3 (1, 7) 2 (1, 7) 3 (1, 7) 3 (1, 8) 0.309
Hospital length of stay, days 6 (3, 14) 7 (3, 15) 6 (2–11) 7 (3, 14) 0.016
Continuous variables are presented as median (IQR) and categorical variables as n (%); ICP, intracranial pressure; APACHE II, acute illness severity and chronic
health evaluation II; TISS-76, therapeutic intervention scoring system 76.
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A total of 298 patients were included in the nested co-
hort (Additional file 1). An average of 6.3 ABG was col-
lected for every patient in the nested cohort. The
median TWA-O2 was 20.9 kPa (IQR 17.1 to 25.2) and
the median nPaO2 was 18.4 kPa (IQR 13.7 to 24.9). The
median IMPACT score was 38 (IQR 22 to 54). No statis-
tical significant correlation between the IMPACT score
and nPaO2 or TWA-O2 was found (Spearman correlation
coefficient −0.027 (P = 0.638) and −0.19 (P = 0.741), re-
spectively) (Additional file 2). Hence, we showed that
there was no co-linearity between TBI severity and PaO2.
Furthermore, there was statistically significant correlation
between TWA-O2 and nPaO2 (Spearman correlation coef-
ficient 0.688, P <0.001) (Additional file 3). Thus, we





Mortality, number of patients (%)
In-ICU 201 (18) 42 (24)
In-hospital 313 (28) 64 (37)
6-month 435 (39) 83 (48)APACHE II methodology accurately describes the pa-
tients’ oxygenation state during the whole mechanical
ventilation period and is not influenced by TBI severity.
Outcome
Unadjusted outcomes are presented in Table 2. The
overall total 6-month mortality was 39% (n = 435). Of
the non-survivors, 46% (n = 201) died in the ICU and
72% died in hospital before they could be discharged.
In univariate analysis, hyperoxemic patients had signifi-
cantly lower 6-month and in-hospital mortality compared
to normoxemic and hypoxemic patients (P = 0.012 and
0.014, respectively). However, after adjusting for
confounding factors in a multivariate logistic regression
model, hyperoxemia had no independent relationship with







61 (16) 98 (17) 0.067
105 (28) 144 (25) 0.014
151 (40) 201 (35) 0.012
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tio (OR) = 0.88, 95% CI 0.63, 1.22 (P = 0.429); for
hyperoxemia versus hypoxemia, OR = 0.97, 95% CI 0.63,
1.50 (P = 0.898) (Table 3). The same results were noted for
in-hospital mortality. There was no significant co-linearity
between variables in the final multivariate analysis
(VIFmax = 1.13). The underlying relationship between
predicted risk of death and PaO2 is shown with a
lowess smoother curve in Figure 2. The mean predicted
risk for 6-month mortality was 38.9% (SD 27.0) and for
in-hospital mortality it was 27.7% (SD 25.0). There was
significant variation between the groups in the pre-
dicted probability of death, it being highest in the hyp-
oxemia group and lowest in the hyperoxemia groups (P
<0.001) (Figures 3 and 4). To further investigate the re-
lationship between hyperoxemia and outcome, PaO2
values were divided by deciles. Hyperoxemic PaO2 deciles
were compared to normoxemic deciles in a multivariate
analysis adjusting for same variables as above. However,
even after dividing PaO2 by deciles, no statistically signifi-




We conducted a large multicenter retrospective observa-
tional study investigating the relationship between
hyperoxemia in the first 24 h after ICU admission and
long-term mortality in patients with moderate-to-severe
TBI. Initially, in univariate analysis a significant associ-
ation between hyperoxemia and decreased risk of death
was noted. However, after adjusting for illness severity in
multivariate analysis, no association between hyperoxemia
and outcome was noted. The results remained whenTable 3 Adjusted outcomes by multivariable logistic
regression model showing relationship between PaO2
groups and outcome
Variable Odds ratio (95% CI) P-value
6-month mortality
Hypoxemia versus normoxemia 0.90 (0.57, 1.41) 0.648
Hyperoxemia versus normoxemia 0.88 (0.63, 1.22) 0.429
Hyperoxemia versus hypoxemia 0.97 (0.63, 1.50) 0.898
In-hospital mortality
Hypoxemia versus normoxemia 1.01 (0.63, 1.62) 0.967
Hyperoxemia versus normoxemia 0.94 (0.65, 1.36) 0.753
Hyperoxemia versus hypoxemia 0.93 (0.59, 1.47) 0.766
Multivariate analysis adjusted for acute physiology and chronic health
evaluation II (APACHE II) index independent of oxygenation (AP2no-ox),
admission year (before or after 2007), emergency operation, intracranial
pressure monitoring, controlled hypothermia and platelet count. PaO2 (arterial
oxygen tension) groups: hypoxemia, <10.0 kPa; normoxemia, 10.0 to 13.3 kPa;
hyperoxemia, >13.3 kPa. The multivariable model displayed excellent
discrimination (area under the curve 0.82, 0.83) and calibration (RL
2 = 0.708, 0, 119)
for predicting 6-month mortality and in-hospital mortality, respectively.dividing PaO2 by deciles. Thus, no consistently reprodu-
cible independent relationship between hyperoxemia and
outcome was determined.Comparison with other studies
The deleterious effect of hypoxemia in TBI patients is well
known [3]. Acknowledge guidelines advocate PaO2 values
between 8.0 and 13.3 kPa (60-100 mmHg) [5,6,20].
Normobaric hyperoxia therapy during ICU care is a
commonly used treatment alternative providing a safe
margin to hypoxemia [22,23]. However, the use of
hyperoxia (normobaric) is not without problems and ex-
perimental research has provided data indicating harm-
ful effects of hyperoxia exposure due to increased free
radical damage, activation of programmed cell death
pathways and expression of pro-inflammatory and anti-
inflammatory cytokines, ultimately leading to cell death
and causing acute lung injury, with similar histopatho-
logical findings to acute respiratory distress syndrome
(ARDS) [24-26]. Previous studies have shown that ap-
proximately 20 to 30% of all patients with severe TBI de-
velop acute lung injury (ALI)/ARDS, resulting in poorer
long-term outcomes [27]. Suggested etiologies of ALI/
ARDS in patients with TBI include the use of high tidal
volume, high respiratory rate, aspiration, pneumonia,
and neurogenic pulmonary edema [28]. Furthermore,
normobaric hyperoxia therapy has been shown to cause
cerebral vasoconstriction, reducing cerebral perfusion,
which may potentially increase cerebral ischemia [29,30].
However, experimental studies by Singhal et al. have
suggested that the benefits of normobaric hyperoxia ex-
posure outweigh the risks [31]. The exact mechanism of
hyperoxia-induced lung injury remains incompletely
understood and there is not enough evidence from clin-
ical studies showing that normobaric hyperoxia treat-
ment (that is, high FiO2) increases the risk of ALI
independent of the underlying disease (for example,
bacterial or viral infections, trauma, chronic lung in-
jury, aspiration, or lung contusion) [25]. Despite the po-
tentially harmful effects, normobaric hyperoxic therapy
has been shown to be beneficial in treating low brain
oxygen levels, together with ICP control and CPP main-
tenance [11,32,33]. When normobaric hyperoxia is ap-
plied it is aimed at keeping PbtO2 greater than 20 to 25
mmHg (2.7 to 3.3 kPa), which is 50% of the normal
brain tissue oxygen levels [34]. Also, the increased oxy-
gen availability with high FiO2 levels may lead to induc-
tion of cerebral aerobic metabolism, alleviating
ischemic injury [35,36].
In 2007 the BTF guidelines presented class III evi-
dence in favor of a PbtO2-targeted therapy in combin-
ation with the traditional CPP/ICP-targeted therapy [7].
Newer studies have reinforced this by showing improved
Figure 2 Locally weighted scatterplot smoothing (lowess) curve showing the relationship between arterial oxygen value (PaO2) and
predicted 6-month mortality. Predicted risk of death showed good performance in predicting actual mortality with an area under the curve
(AUC) of 0.869 and RL
2 of 0.422. A clear association between increased risk of death and low (approximately <11 kPa) PaO2 or values very high
(approximately >42 kPa) PaO2 values was noted. The predicted probability of death is calculated using the following variables: acute physiology
and chronic health evaluation II (APACHE II) index independent of oxygenation (AP2no-ox), admission year (before or after 2007), emergency
operation, intracranial pressure monitoring, controlled hypothermia and platelet count.
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apy compared to using the traditional CPP/ICP therapy
[37,38]. In a review article by Nangunoori et al. the use
of PbtO2-targeted therapy doubled the likelihood of a fa-
vorable neurological outcome in patients with TBI [8].
There are several treatment strategies for maintainingFigure 3 Observed and mean predicted in-hospital mortality differen
in mean predicted risk of death was significantly different among the grou
the hyperoxemia group. Predicted risk of death matched observed mortality
The predicted probability of death was calculated using the following variable
independent of oxygenation (AP2no-ox), admission year (before or after 2007
hypothermia and platelet count.PbtO2, increasing FiO2 and augmenting CPP by ICP-
lowering treatment, vasopressors and fluids being the
most commonly used [9,39]. However, in the presence of
cerebral ischemia, aggressive attempts to maintain CPP
with fluids and vasopressors should be avoided due to
risk of ALI/ARDS [6,40]. Thus, increasing FiO2 toces between arterial oxygen tension (PaO2) groups. The difference
ps (P <0.001), it being highest in the hypoxemia group and lowest in
very well within the quartiles with RL
2 values between 0.097 and 0.746.
s: acute physiology and chronic health evaluation II (APACHE II) index
), emergency operation, intracranial pressure monitoring, controlled
Figure 4 Observed and mean predicted 6-month mortality differences between PaO2 groups. The difference in mean predicted risk of
death is significantly different among the groups (p < 0.001), being highest in the hypoxemia group and lowest in the hyperoxemia group.
Predicted risk of death matched observed mortality very well within the quartiles with RL
2 values between 0.519 and 0.603.
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(hyperoxemia) has a central role in treating a lowered
PbtO2, especially in the presence of adequate ICP and
CPP [37,41]. Whether increasing oxygen in arterial
blood to supra-physiological levels has a positive impact
on cerebral metabolism and improves outcomes remains
to be debated [10,42].
Clinical studies investigating the relationship between
hyperoxia therapy or hyperoxemia and outcome in TBI
patients have come up with controversial results. Tolias
et al. showed in a prospective non-randomized study
that hyperoxia therapy significantly improved cerebral
oxidative metabolism and decreased ICP. This was asso-
ciated with better outcomes, supporting the use of
hyperoxia therapy [32]. Davis et al. showed a reduced
risk of in-hospital mortality in patients with mildFigure 5 Observed and predicted 6-month mortality by deciles of art
risk of death matched observed mortality very well within deciles with RL
2 valu
calculated using the following variables: acute physiology and chronic health
admission year (before or after 2007), emergency operation, intracranial presshyperoxemia (PaO2 15 to 65 kPa) on admission, but in-
creased risk of death in patients with extreme
hyperoxemia (>65 kPa). In a small, retrospective, single-
center study including 193 severe TBI patients, Asher et
al. showed improved survival for hyperoxemic patients
whose PaO2 thresholds were between 33 and 65 kPa
during the first 72 h of admission [43]. In a large, single-
center, retrospective study including 1,547 patients,
Brenner et al. showed a significant association between
hyperoxemia (PaO2 >26.6 kPa) and poor short-term out-
come after TBI. However, the study was not restricted to
patients on mechanical ventilation, which may induce
bias, because it is probable that patients not on mechan-
ical ventilation are likely to have a less severe TBI and
hyperoxemia is more likely with mechanical ventilation
[44]. In this study we avoided this potential confoundingerial oxygen tension (PaO2). PaO2 was divided by deciles. Predicted
es between 0.088 and 0.987. The predicted probability of death was
evaluation II (APACHE II) index independent on oxygenation (AP2no-ox),
ure monitoring, controlled hypothermia and platelet count.
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lation. Similar to the present study, Eastwood et al.
found no association between early hyperoxemia in gen-
eral ICU patients during the first hours of ICU stay, and
in-hospital mortality [45]. This was further confirmed by
Young et al. studying mechanically ventilated ischemic
stroke [46]. Furthermore, studies investigating the rela-
tionship between hyperoxemia and outcome in cardiac
arrest patients have also yielded controversial results
[47,48].
In the present study 6-month mortality was 39%,
which is somewhat higher than previously described.
The IMPACT study showed a 6-month mortality rate of
32%, and the Corticosteroid Randomization After Sig-
nificant Head Injury (CRASH) study showed a 29%
death rate [21,49]. However, one major factor that has to
be considered is the difference in the age of the study
populations, as age is a major prognostic factor in TBI
patients [50]. The median age in our study was 53 years
(IQR 35 to 64) compared to 30 years (IQR 21 to 45) and
32 years (IQR 28 to 47) in the IMPACT and CRASH
studies, respectively [21,49].
In this study we did not find any statistically signifi-
cant reproducible association between hyperoxemia and
6-month mortality in TBI patients treated in the ICU.
This could be a consequence of lack of power. However,
our study suggests that hyperoxemia is safe and a viable
therapy target when trying to avoid the detrimental ef-
fects of hypoxemia and subsequent brain hypoxia. Our
analysis should be extended in future studies to include
all oxygenation values during the first days of TBI treat-
ment. Furthermore, further studies should aim to assess
PbtO2 levels, as this has shown to improve outcome
[37,38,41]. Currently, two highly anticipated studies are
underway investigating the role of normobaric hyperoxia
therapy (BRAINOXY) and the role of PbtO2 targeted
therapy (BOOST 2) in patients with TBI in the ICU.
Strengths and limitations
Our study has several strengths. First, it includes 1,116
patients, making it one of the largest studies of its type
conducted so far. Second, our data come from a large,
multicenter high-quality database reflecting almost all
ICUs in Finland [17]. Third, this is the first study of its
kind using 6-month mortality as primary endpoint,
which considerably strengthens the credibility of this
study, as it has been shown that in-hospital mortality se-
verely underestimates mortality in TBI patients [49]. We
acknowledge some limitations with our study. Most im-
portantly the only available oxygen value was the worst
one, according to the APACHE II methodology, which
carries the risk of not fully describing the patient’s oxy-
genation situation during the whole mechanical ventila-
tion period. However, as we showed with the nestedcohort analysis the PaO2 measured using the APACHE
II methodology describes the mechanical ventilation
period very well. Also, our statistical approach is partly
limited to standard statistical methods comparing three
levels of oxygenation, which, however, is a physiological
process and not linear in nature. However, the lowess
smoother analysis (Figure 2) does not assume any linear-
ity in association. Second, we cannot control for oxygen
exposure prior to ICU admission. Third, due to the
retrospective nature of this study we used the APACHE
II model to adjust for illness severity. However, this po-
tential confounding factor was controlled for by
performing the nested cohort analysis. Fourth, due to
the retrospective nature of the study we were unable to
assess long-term neurological outcome and were limited
to using long-term mortality as the primary endpoint.
Finally, because all institutions use the traditional CPP/
ICP-directed therapy as standard TBI care we cannot
comment on whether a PbtO2-targeted therapy would
have improved the outcomes in our study.
Conclusion
Hyperoxemia in the first 24 h of ICU admission after a
moderate-to-severe TBI was not independently associ-
ated with 6-month mortality.
Key messages
 No consistent reproducible relationship between
hyperoxemia and risk of death was established.
 Targeting hyperoxemia seems to be a safe approach
when trying to maintain adequate brain oxygenation.
 Extreme hyperoxemia should be used with caution.
Additional files
Additional file 1: Table S1. Nested cohort analysis patient characteristics.
Additional file 2: Figure S1. Correlation between International Mission
for Prognosis and Clinical Trials (IMPACT) score in traumatic brain injury
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Additional file 3: Figure S2. Correlation between the time weighted
average of arterial oxygen tension during the whole mechanical ventilation
period (TWA-O2) and arterial oxygen tension when the alveolar-arterial
gradient is the highest or oxygen value the lowest for patients in the nested
cohort (nPaO2), measured using the acute physiology and chronic health
evaluation II (APACHE II) methodology in patients in the nested cohort.
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